That's a work in progress. It's all contingent on the investigation and all will be revealed when the investigation comes. As a rule. The way to think about this as journalists is The 301 actions by the USTR are generally but not always country specific, whereas the 232s are product specific. Okay, what else you got? Yes, sir. Generic pharmaceutical drugs and the patented or new high end drugs. The heavy. Good question. The heavy focus is on the generics. (08:11–08:25)
CLAIM
Asserts the distinction between 301 and 232 trade actions by the USTR.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
